The Ken and Ruth Davee Department of Neurology faculty members who specialize in clinical neuroimmunology focus on education, research, and clinical therapeutics and treatment of multiple sclerosis (MS) and related inflammatory diseases of the central nervous system, including neuromyelitis optica, acute disseminated encephalomyelitis, transverse myelitis, and monophasic demyelinating syndromes. Through Northwestern University Feinberg School of Medicine's affiliated care institutions, we treat patients with neurosarcoidosis and other CNS autoimmune disorders.
We provide training opportunities for neurology residents in diagnosis, treatment and longitudinal care issues of MS patients with a wide spectrum of clinical presentation ranging from minimal to severe neurological impairment. All currently approved MS therapeutics are used in the program. A post residency fellowship in clinical multiple sclerosis care is available which offers more extensive training including opportunities to participate in clinical therapeutic trials and to see pediatric MS patients and MS focused rehabilitation therapy at collaborating program clinics in pediatric neurology at Ann & Robert H. Lurie Children’s Hospital of Chicago and the Rehabilitation Institute of Chicago. Opportunities for medical students wishing to pursue educational experiences outside the third year neurology rotation are available.
Faculty also provide continuing medical educational programs on MS for physicians in practice, and a monthly program for patients with MS.
The division conducts clinical research trials related to multiple sclerosis therapeutics including studies of novel agents.
Current clinical trials include:
- A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis
- A randomized double-blind, double –dummy, parallel –group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta -1a in patients with relapsing multiple sclerosis
- A randomized, double-blind, placebo –controlled study to evaluate the safety, tolerability, and activity of ibudilast (MN-166) in subjects with progressive multiple sclerosis
- JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri: STRATIFY-2
Through our affiliated care sites, our faculty specialists administer a comprehensively focused multiple sclerosis treatment program, established in 1986. The program was the first National Multiple Sclerosis Society certified comprehensive MS treatment center in the Midwest. It provides diagnostic and second opinion services, administers both disease modifying and symptomatic treatments for multiple sclerosis and related disorders on a longitudinal basis, addresses rehabilitation and maintenance of function needs through its component at the Rehabilitation Institute of Chicago, and includes a pediatric MS clinic at the Lurie Children’s.
Meet Our Faculty
Access neuroimmunology faculty bios to learn more about their work within this specialty.